Farmacosmo Valuation Multiples

Farmacosmo is valued at $18M as of November 2026, a 0.4x revenue multiple. In the last fiscal year, Farmacosmo revenue was $62M and Farmacosmo EBITDA was $370K.

Farmacosmo Overview

About Farmacosmo

Farmacosmo is an Italian company that sells medicines, food supplements, over-the-counter products and beauty and personal-care items online, with offices in Naples. It runs the farmacosmo.it portal and a group of other web shops covering perfumery, pet care and digital health, and fulfils up to 12,000 orders a day from its own logistics base. The shares were admitted to Euronext Growth Milan in March 2022, raising EUR 20 million in the placement at a market capitalisation of EUR 75.3 million. After the listing it bought the ProfumeriaWeb perfumery portal, the Phàrmasi online pharmacy with its Messina store, a majority of Innovation Pharma, which owns two pharmacies, and Bau Cosmesi. In 2025 it sold control of Bau Cosmesi and bought out the remaining shareholder of Farmacia De Leo, ending its involvement in the physical Messina pharmacy.


Founded

2013

HQ

Italy

Employees

N/A

Financials (Last FY)

Revenue: $62M
EBITDA: $370K

EV

$25M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Farmacosmo Financials

Farmacosmo reported last fiscal year revenue of $62M and EBITDA of $370K.

In the same fiscal year, Farmacosmo generated $17M in gross profit, $370K in EBITDA, and had net loss of ($5M).


Farmacosmo P&L

In the most recent fiscal year, Farmacosmo reported revenue of $62M and EBITDA of $370K.

Farmacosmo is unprofitable as of last fiscal year, with gross margin of 27%, EBITDA margin of 1%, and net margin of (8%).

See analyst estimates for Farmacosmo
Last FY202320242025202620272028
Revenue$62M$83M$73M$62M
Gross Profit$17M$18M$19M$17M
Gross Margin27%22%26%27%
EBITDA$370K($469K)$843K$370K
EBITDA Margin1%(1%)1%1%
EBIT Margin(10%)(4%)(3%)(10%)
Net Profit($5M)($4M)($3M)($5M)
Net Margin(8%)(5%)(5%)(8%)
Net Debt$7M---

Financial data powered by Morningstar, Inc.

Farmacosmo Stock Performance

Farmacosmo has current market cap of $18M, and enterprise value of $25M.

Market Cap Evolution


Farmacosmo's stock price is $0.46.

Farmacosmo share price increased by 0.1% in the last 30 days, and decreased by 5.1% in the last year.

Farmacosmo has an EPS (earnings per share) of $-0.13.

See more trading valuation data for Farmacosmo
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$25M$18M2.5%0.1%-18.3%-5.1%$-0.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Farmacosmo Valuation Multiples

Farmacosmo trades at 0.4x EV/Revenue multiple, and 66.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Farmacosmo

Farmacosmo Financial Valuation Multiples

As of November 8, 2026, Farmacosmo has market cap of $18M and EV of $25M.

Farmacosmo has a P/E ratio of (3.6x).

Last FY202320242025202620272028
EV/Revenue0.4x0.3x0.3x0.4x
EV/EBITDA66.6x(52.6x)29.3x66.6x
EV/EBIT(4.0x)(7.0x)(10.4x)(4.0x)
EV/Gross Profit1.5x1.3x1.3x1.5x
P/E(3.6x)(4.7x)(5.2x)(3.6x)
EV/FCF(10.2x)(3.0x)(6.3x)(10.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Farmacosmo Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Farmacosmo Margins & Growth Rates

Farmacosmo decreased revenue by 27% but EBITDA grew by 396% in the last fiscal year.

In the most recent fiscal year, Farmacosmo reported gross margin of 27%, EBITDA margin of 1%, and net margin of (8%).

See estimated margins and future growth rates for Farmacosmo

Farmacosmo Margins

Last FY202420252026202720282029
Gross Margin27%26%27%52%
EBITDA Margin1%1%1%4%
EBIT Margin(10%)(3%)(10%)(2%)
Net Margin(8%)(5%)(8%)(3%)
FCF Margin(4%)(5%)(4%)(6%)

Farmacosmo Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(27%)(11%)(15%)(27%)
Gross Profit Growth42%5%(14%)42%
EBITDA Growth396%(280%)(56%)396%
EBIT Growth(88%)(32%)158%(88%)
Net Profit Growth(73%)(8%)45%(73%)
FCF Growth20%(53%)(38%)20%

Data powered by FactSet, Inc. and Morningstar, Inc.

Farmacosmo Operational KPIs

Farmacosmo's Rule of 40 is (23%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Farmacosmo's Rule of X is (64%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Farmacosmo
Last FY202320242025202620272028
Rule of 40(23%)---
Bessemer Rule of X(64%)---
Opex to Revenue36%26%30%36%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Farmacosmo Competitors

Farmacosmo competitors include Acetech E-Commerce, Adore Beauty, Studio Samick, Bubbleroom, Confinvest Oro, Rise, Nomadar, MOGU, Pet Service Holding and Hamee.

Most Farmacosmo public comparables operate across Consumer E-commerce, Pharmacies, Vertical E-commerce and HealthTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Acetech E-Commerce$9M$2M1.7x-9.9x-
Adore Beauty$144M$3M0.3x0.3x14.5x11.7x
Studio Samick$71M$3M0.0x0.0x0.7x-
Bubbleroom$43M($1M)0.2x-(8.0x)-
Confinvest Oro$91M$2M0.3x0.2x9.7x8.3x
Rise$3M$879K4.5x4.5x14.0x-
Nomadar$922K($3M)23.8x-(7.8x)-
MOGU$19M$2M----

This data is available for Pro users. Sign up to see all Farmacosmo competitors and their valuation data.

Start Free Trial

Acquisitions by Farmacosmo

Farmacosmo has acquired 6 companies to date.

Last acquisition by Farmacosmo was on December 15th 2025. Farmacosmo acquired Farmacia De Leo for $6M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Farmacosmo

Farmacia De Leo
FRCM1
Bau Cosmesi
Innovation Pharmaceuticals
Description
Farmacia De Leo is an Italian company based in Messina that owned the De Leo pharmacy and the Phàrmasi online pharmacy portal, which was founded in 2010. Phàrmasi was one of the long-established Italian operators in online health, pharma and beauty retail, with more than 16,000 references in its catalogue. In 2021 the company recorded revenue of about EUR 5.2 million, of which EUR 3.1 million came from the portal and over EUR 2.1 million from the physical pharmacy, with EBITDA of around EUR 0.3 million. It was founded by Rosario De Leo, who stayed on as chairman after Farmacosmo bought a majority in 2022. In December 2025 its pharmacy business was transferred to Nica Sgroi S.r.l., a company linked to Rosario De Leo, leaving Farmacia De Leo as the owner of the pharmasi.it e-commerce portal.
FRCM1 is an Italian company that owns the FarmaWoW portal, an e-commerce site in pharma and beauty with more than 43 thousand references in its catalogue. In the first six months of 2023 it reported revenues of about EUR 750,000 from about 12,000 orders, at an average order value of about EUR 68. Its EBITDA margin was about 3 percent and its net financial position was close to zero. It was owned by MP Holding S.r.l., traceable to Maria Palomba, until September 2023. After the sale Farmacosmo held 51 percent and Erfo 49 percent, and in December 2024 Farmacosmo bought the Erfo stake and took 100 percent.
Bau Cosmesi is an Italian company that sells pet-care products under the BauBau brand. Farmacosmo took a majority stake in it in early 2023, when the company had revenue of more than EUR 0.3 million for 2022. The founder, Andrea Bianchi, kept a minority holding and stayed in the business. By the end of 2025 the company had been agreed to be worth EUR 10 million, with an earn-out linked to 2026 EBITDA above EUR 1.2 million. The business holds a positive net cash balance, which the buyer in the 2025 sale agreed to pay for.
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.
HQ CountryItalyItalyItalyUnited States
HQ City
Messina
Naples
-
-
Deal Date15 Dec 202525 Oct 20243 Feb 202321 Dec 2022
Valuation$6M$337Kundisclosed$4M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Farmacosmo acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Farmacosmo

Farmacosmo has invested in 1 company to date.

Latest investment by Farmacosmo was on November 12th 2025. Farmacosmo invested in 2Watch in their Undisclosed stage round.

See VC round multiples

Latest Investments by Farmacosmo

2Watch
Description
2Watch is a marketing and software development firm based in Los Angeles, California. It builds Twitch channels, proprietary streaming apps, and creator networks for esports and entertainment. Services include ad campaigns on YouTube and TikTok alongside custom game integrations. Founded in 2021, 2Watch supports over 100 content creators with analytics dashboards.
HQ CountryItaly
HQ City
-
Deal Date12 Nov 2025
RoundUndisclosed stage
Raisedundisclosed
InvestorsFarmacosmo; Alessandro Avallone; Massimo Petrella; Francesco Norcia; Donatello Bianco; Pathfinder; Luca La Mesa; Stefano Bassi; SideAngels; Fabio Lalli
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Farmacosmo investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Farmacosmo

When was Farmacosmo founded?Farmacosmo was founded in 2013.
Where is Farmacosmo headquartered?Farmacosmo is headquartered in Italy.
Is Farmacosmo publicly listed?Yes, Farmacosmo is a public company listed on Borsa Italiana.
What is the stock symbol of Farmacosmo?Farmacosmo trades under COSMO ticker.
When did Farmacosmo go public?Farmacosmo went public in 2022.
Who are competitors of Farmacosmo?Farmacosmo main competitors include Acetech E-Commerce, Adore Beauty, Studio Samick, Bubbleroom, Confinvest Oro, Rise, Nomadar, MOGU, Pet Service Holding, Hamee.
What is the current market cap of Farmacosmo?Farmacosmo's current market cap is $18M.
What is the current revenue of Farmacosmo?Farmacosmo's last fiscal year revenue is $62M.
What is the current revenue growth of Farmacosmo?Farmacosmo revenue growth (vs. last FY) is (27%).
What is the current EV/Revenue multiple of Farmacosmo?Current revenue multiple of Farmacosmo is 0.4x.
Is Farmacosmo profitable?No, Farmacosmo is not profitable.
How many companies Farmacosmo has acquired to date?As of November 2026, Farmacosmo has acquired 5 companies.
What was the largest acquisition by Farmacosmo?$6M acquisition of Farmacia De Leo on 15th December 2025 was the largest M&A Farmacosmo has done to date.
What companies Farmacosmo acquired?Farmacosmo acquired Farmacia De Leo, Innovation Pharmaceuticals, ProfumeriaWeb, FRCM1, and Bau Cosmesi.
In how many companies Farmacosmo has invested to date?As of November 2026, Farmacosmo has invested in 1 company.
What was the last Farmacosmo investment?On 12th November 2025 Farmacosmo invested in 2Watch, participating in a Undisclosed stage round, alongside Alessandro Avallone, Massimo Petrella, Francesco Norcia, Donatello Bianco, Pathfinder, Luca La Mesa, Stefano Bassi, SideAngels, and Fabio Lalli.
In what companies Farmacosmo invested in?Farmacosmo invested in 2Watch.

See public comps similar to Farmacosmo

Lists including Farmacosmo

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial